Kras mutations have been tightly linked to tumor-mediated inflammation and tumorigenesis through several induced inflammatory cytokines, chemokines (Golay and Barbie, 2014; Kitajima et al., 2016). The gene discussed is KRAS; the disease is neoplasm.